Healthcare / Medical DistributionNasdaqCM
$0.26
+0.01 (+3.95%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-9.0M · quality 60.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$14M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-103.9%
↓Gross Margin
12.1%
↓Debt/Equity
1.08
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-13.2%
FCF / Net income
0.45x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $65.3M · net income $-19.1M · FCF $-8.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $65.3M | $65.3M | $54.4M | $53.4M | $50.3M | $56.2M | $55.4M | $39.7M | $37.1M | $30.0M | $6.8M | $533802.00 | $7.6M | $902369.00 | — | — | — |
| Net Income | $-19.1M | $-19.1M | $-16.2M | $-18.5M | $-13.8M | $-8.0M | $820786.00 | $-3.3M | $-9.1M | $-6.2M | $-601002.00 | $-6.7M | $6.0M | $246592.00 | $-455.00 | $-169245.00 | $-3.8M |
| EBITDA | $-15.2M | $-15.2M | $-13.9M | $-17.1M | $-8.9M | $-4.2M | $3.1M | $138819.00 | $-1.2M | — | — | — | — | — | — | — | — |
| EPS | — | — | -1.17 | -2.15 | -33.16 | -23.74 | 0.06 | -0.25 | -0.68 | -0.49 | 80741.00 | -0.50 | 0.50 | 0.00 | 0.00 | — | — |
| Gross Margin | 12.1% | 12.1% | 7.9% | 8.1% | 11.8% | 14.8% | 14.5% | 9.2% | 6.5% | 6.5% | 8.9% | 9.2% | 100.0% | — | — | — | — |
| Operating Margin | -25.3% | -25.3% | -28.0% | -40.9% | -14.8% | -8.1% | 4.9% | -0.6% | -3.3% | -16.2% | -3.0% | -82.9% | 93.2% | 32.0% | — | — | — |
| Net Margin | -29.3% | -29.3% | -29.7% | -34.7% | -27.5% | -14.2% | 1.5% | -8.3% | -24.4% | -20.7% | -8.9% | -1252.9% | 79.1% | 27.3% | — | — | — |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 1.08 | 1.08 | 0.48 | 0.34 | 0.30 | 0.11 | -2.59 | 0.00 | -0.04 | — | — | — | — | — | — | — | — |
| Current Ratio | 1.08 | 1.08 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-8.6M | $-8.6M | $-9.0M | $-24.8M | $-15.3M | $-7.7M | $-11.6M | — | $-2.1M | $-8.8M | $-2.1M | $-541041.00 | $6.5M | — | — | — | — |
| Returns | |||||||||||||||||
| ROE | -103.9% | -103.9% | -66.0% | -51.4% | -34.9% | -181.8% | -19.7% | 51.1% | 273.1% | 205.1% | 34.3% | 536.0% | 110.4% | -459.3% | 32.4% | 3554.1% | 21670.6% |
| Valuation | |||||||||||||||||
| P/B | 0.59 | 0.59 | 0.55 | 0.40 | 0.22 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | 19.9% | 19.9% | 2.0% | 6.0% | — | 1.5% | 39.6% | 7.0% | 23.6% | 344.3% | 1165.5% | -93.0% | 746.6% | — | — | — | — |
| EPS Growth | — | — | 45.6% | 93.5% | — | -39666.7% | 124.0% | 63.2% | -38.8% | -100.0% | 16148300.0% | -200.0% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-42.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.17 → n/d
Residual
-42.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.